Article
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
The Lancet. Oncology - 1 Feb 2015
Farooqui Mohammed Z H, Valdez Janet, Martyr Sabrina, Aue Georg, Saba Nakhle, Niemann Carsten U, Herman Sarah E M, Tian Xin, Marti Gerald, Soto Susan, Hughes Thomas E, Jones Jade, Lipsky Andrew, Pittaluga Stefania, Stetler-Stevenson Maryalice, Yuan Constance, Lee Yuh Shan, Pedersen Lone B, Geisler Christian H, Calvo Katherine R, Arthur Diane C, Maric Irina, Childs Richard, Young Neal S, Wiestner Adrian
Abstract excerpt
BACKGROUND: Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations respond poorly to first-line chemoimmunotherapy, resulting in early relapse and short survival. We investigated the safety and activity of ibrutinib in previously untreated and relapsed or refractory CLL with TP53 aberrations. METHODS: In this investigator-initiated, single-arm phase 2 study, we enrolled eligible adult patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.